VILYA, Inc. Secures $71M in Expanded Series A Financing to Advance Precision Medicine

Seattle, WA, June 4, 2024 (Globe newswire) -- VILYA, Inc. (Vilya), a biotechnology company pioneering a new class of medicines with precise targeting of disease biology, announced today an expanded Series A financing round totaling $71 million. The round is led by ARCH Venture Partners, the founder and lead investor, and includes significant contributions from leading life science and technology funds such as NVIDIA’s venture capital arm NVentures, Menlo Ventures, Madrona, Lifeforce Capital, and Altitude Life Science Ventures.

Read full article here.